We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Calls for Flexible Biosimilars Standards as Public Meeting Begins
Teva Calls for Flexible Biosimilars Standards as Public Meeting Begins
November 2, 2010
Teva is calling on the FDA to adopt flexible standards once it approves a biosimilar for its initial indication, saying that no additional testing should be required to have a product deemed interchangeable or to approve additional indications.